JAK2 and Splenomegaly: Between the time of diagnosis and the time of ruxolitinib start, clinical and hematological features worsened in both JAK2 and CALR cohorts, with progressive increase of leukocytes, blast counts, splenomegaly and symptoms, and decrease of hemoglobin levels and platelet counts (Supplemental Table 1).